Wegovy results in men: what the trial data says

What the STEP trials recorded for male participants

The foundational evidence for semaglutide 2.4mg comes from the STEP programme, with STEP 1 being the largest of the weight-management trials, 1,961 adults with obesity or overweight plus a weight-related condition, followed for 68 weeks. The paper published in the New England Journal of Medicine reported an overall average weight reduction of around 14.9% in the semaglutide group, versus roughly 2.4% with placebo.

Sub-group analyses showed men averaged slightly lower percentage losses than women (broadly in the 12–14% range depending on the analysis) but the absolute weight change told a different story. Because men in these trials started at higher average body weights, the actual kilograms shed were often comparable to, or greater than, those lost by female participants. A man starting at 120 kg losing 13% has dropped around 15.6 kg. That is not a consolation figure. It is a clinically relevant reduction with real consequences for blood pressure, cholesterol, joint load and cardiovascular risk.

The sex difference in percentage terms is partly explained by body composition: women carry a higher proportion of body fat relative to lean mass, and fat tissue responds more readily to the caloric deficit that semaglutide helps create. Men have more lean mass, which is metabolically active but not itself subject to the same degree of loss. This is biology, not a flaw in the medicine.

For men who want to see what the broader Wegovy results data looks like across the full trial population, our dedicated results page sets it out in detail.

How quickly men tend to notice a difference on Wegovy

The dose escalation schedule begins at 0.25mg and rises gradually over roughly 16 weeks toward the 2.4mg maintenance dose, guided by the prescriber. Most people (men included) begin to notice a reduction in appetite and some early weight change before they reach the full dose. The first-week experience is usually dominated by tolerability rather than dramatic scale movement; the most meaningful losses accumulate over months, not days.

Men often report noticing the appetite suppression effect quite clearly, a reduced drive to eat larger portions, less preoccupation with food between meals. That subjective shift tends to arrive before the scale confirms it. Studies tracking progress week by week show steady, cumulative loss rather than a dramatic early drop followed by a plateau. If you are curious about what Wegovy's two-week results typically look like and how that early picture fits into the broader pattern of change, that page sets out what the evidence actually shows. If you are curious about the pace at which changes compound, the timeline for how long Wegovy takes to work covers what is typical at each stage.

One misconception worth setting aside gently: some men arrive expecting results within a fortnight or conclude early on that it is not working for them. The evidence does not support that timeframe for most people. Meaningful, sustained loss at the doses studied took the better part of a year. Patience with the process is not a platitude, it is what the trial design actually reflects.

Factors that shape how much weight a man loses on Wegovy

Trial averages are population figures. Individual results vary, and several factors influence where a particular man lands relative to that average. Starting BMI matters: those with higher starting weights tend to lose more in absolute terms. Dietary habits alongside treatment matter too, semaglutide reduces appetite but does not override a consistently high calorie intake. Physical activity, particularly resistance training (which preserves lean mass during weight loss), is associated with better body composition outcomes even if the scale difference is modest.

Adherence to the escalation schedule and staying at the maintenance dose for the full treatment period both affect outcomes. The reasons some people lose weight more slowly on Wegovy are worth understanding if progress feels slower than expected, because several are addressable with the right clinical support.

Semaglutide is also being studied and used across a broader range of conditions. The NHS medicines page for semaglutide provides accurate, up-to-date information on how it works, common side effects and who it is suitable for, a reliable starting point for anyone wanting an authoritative overview before their consultation.

For men interested in how semaglutide's results compare with those of the other main injectable option, the semaglutide results for men page covers the wider evidence picture, including comparisons with tirzepatide trial data.

Getting started with a clinical assessment

Wegovy is a prescription-only medicine. No weight or sex characteristic alone determines clinical suitability, a prescriber considers the full picture: your BMI, any existing health conditions, your medication history and your goals. Lower BMI thresholds apply for some ethnic backgrounds under current UK guidance, so eligibility is worth checking even if you are not sure you qualify.

At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber, not by an automated system. Our clinical pharmacy is GPhC-registered (registration 9012878, verifiable at the GPhC register). If treatment is appropriate and you order before noon Monday to Friday, it is dispatched the same day and arrives the next working day via DPD in plain packaging, no subscription, no hidden fees.

If you are ready to see whether Wegovy is right for you, start your free consultation and a prescriber will review your answers the same day.